DE69532279D1 - Methoden und zusammensetzung zur inhibition der angiogenese - Google Patents

Methoden und zusammensetzung zur inhibition der angiogenese

Info

Publication number
DE69532279D1
DE69532279D1 DE69532279T DE69532279T DE69532279D1 DE 69532279 D1 DE69532279 D1 DE 69532279D1 DE 69532279 T DE69532279 T DE 69532279T DE 69532279 T DE69532279 T DE 69532279T DE 69532279 D1 DE69532279 D1 DE 69532279D1
Authority
DE
Germany
Prior art keywords
angiogenesis
inhibition
composition
methods
admin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69532279T
Other languages
English (en)
Other versions
DE69532279T3 (de
DE69532279T2 (de
Inventor
Peter Brooks
David A Cheresh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22783992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69532279(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of DE69532279D1 publication Critical patent/DE69532279D1/de
Application granted granted Critical
Publication of DE69532279T2 publication Critical patent/DE69532279T2/de
Publication of DE69532279T3 publication Critical patent/DE69532279T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69532279T 1994-03-18 1995-03-09 Methoden und zusammensetzung zur inhibition der angiogenese Expired - Lifetime DE69532279T3 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/210,715 US5753230A (en) 1994-03-18 1994-03-18 Methods and compositions useful for inhibition of angiogenesis
US210715 1994-03-18
US366665 1994-12-30
US08/366,665 US5766591A (en) 1994-03-18 1994-12-30 Methods and compositions useful for inhibition of angiogenesis
EP95913644A EP0754059B2 (de) 1994-03-18 1995-03-09 Methoden und zusammensetzung zur inhibition der angiogenese
PCT/US1995/003035 WO1995025543A1 (en) 1994-03-18 1995-03-09 Methods and compositions useful for inhibition of angiogenesis

Publications (3)

Publication Number Publication Date
DE69532279D1 true DE69532279D1 (de) 2004-01-22
DE69532279T2 DE69532279T2 (de) 2004-09-16
DE69532279T3 DE69532279T3 (de) 2011-11-17

Family

ID=22783992

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69536128T Expired - Lifetime DE69536128D1 (de) 1994-03-18 1995-03-09 Methoden und Zusammensetzungen zur Inhibition der Angiogenese
DE69532279T Expired - Lifetime DE69532279T3 (de) 1994-03-18 1995-03-09 Methoden und zusammensetzung zur inhibition der angiogenese

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69536128T Expired - Lifetime DE69536128D1 (de) 1994-03-18 1995-03-09 Methoden und Zusammensetzungen zur Inhibition der Angiogenese

Country Status (25)

Country Link
US (7) US5753230A (de)
EP (3) EP0754059B2 (de)
JP (2) JP4268222B2 (de)
KR (1) KR100327081B1 (de)
CN (1) CN1161152C (de)
AT (3) ATE490784T1 (de)
AU (1) AU709645B2 (de)
CA (1) CA2184493C (de)
CZ (1) CZ294650B6 (de)
DE (2) DE69536128D1 (de)
DK (3) DK1468695T3 (de)
ES (3) ES2211901T5 (de)
FI (1) FI121916B (de)
HK (1) HK1013960A1 (de)
HU (1) HU221988B1 (de)
MX (1) MX9604145A (de)
NO (1) NO322441B1 (de)
NZ (3) NZ283022A (de)
PT (2) PT754059E (de)
RU (1) RU2162712C2 (de)
SI (1) SI0754059T2 (de)
SK (1) SK284586B6 (de)
UA (1) UA44729C2 (de)
WO (1) WO1995025543A1 (de)
ZA (1) ZA952214B (de)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6949511B1 (en) 1994-04-26 2005-09-27 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
EP0719859B1 (de) * 1994-12-20 2003-07-02 MERCK PATENT GmbH Monoklonaler Antikörper gegen das Alpha-V-Integrin
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
CN1313146C (zh) * 1995-08-14 2007-05-02 斯克里普斯研究学院 用于抑制αvβ5介导的血管生成的方法和组合物
RU2196769C2 (ru) 1995-08-30 2003-01-20 Джи. Ди. Сирл Энд Ко. Производные аминобензойной кислоты, фармацевтическая композиция
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
CN1202932A (zh) 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
DE69727582T2 (de) * 1996-08-15 2004-12-23 Novartis Ag Test zur quantifizierung von arthritiszustanden
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
EP0846702B1 (de) * 1996-12-09 2009-03-11 MERCK PATENT GmbH Löslicher, rekombinanter alphaV beta3 Adhäsionsrezeptor
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
AU6702998A (en) * 1997-03-12 1998-09-29 Smithkline Beecham Corporation Anti-alphabeta3 humanized monoclonal antibodies
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US5994388A (en) * 1997-03-18 1999-11-30 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
AU6569198A (en) * 1997-03-19 1998-10-12 Lucid Technologies, Inc. Cellular surgery utilizing confocal microscopy
WO1998046265A1 (en) * 1997-04-11 1998-10-22 G.D. Searle & Co. Methods for using antagonistic anti-avb3 integrin antibodies
CA2284726A1 (en) * 1997-04-11 1998-10-22 G.D. Searle & Co. Antagonistic anti-avb3 integrin antibodies
US6596276B1 (en) * 1997-09-30 2003-07-22 Beth Israel Deaconess Medical Center Method for inhibiting tumor angiogenesis in a living subject
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
US6172256B1 (en) * 1998-03-04 2001-01-09 G.D. Searle & Co. Chiral-β-amino acid compounds and derivatives thereof
JP4487019B2 (ja) 1998-03-31 2010-06-23 ランサス メディカル イメージング インコーポレイテッド 血管新生疾患を画像化するための薬剤
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) * 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US7387779B2 (en) * 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
EP1096955B9 (de) 1998-07-13 2006-07-05 Board of Regents, The University of Texas System Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
RU2167425C2 (ru) * 1998-07-17 2001-05-20 Малышев Игорь Юрьевич Способ определения белков
US6164281A (en) * 1998-07-20 2000-12-26 Zhao; Iris Ginron Method of making and/or treating diseases characterized by neovascularization
CA2338283A1 (en) * 1998-08-13 2000-02-24 G.D. Searle & Co. Multivalent avb3 and metastasis-associated receptor ligands
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6248327B1 (en) 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US7176289B1 (en) * 1998-09-11 2007-02-13 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US20030202977A1 (en) * 1998-11-16 2003-10-30 New York University Treatment of osteoarthritis
US6235877B1 (en) 1999-08-04 2001-05-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
ES2242437T3 (es) * 1998-11-20 2005-11-01 Genentech, Inc. Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares.
US6339062B1 (en) * 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
EP1140864A2 (de) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Pharmazeutische zusammensetzungen, vitronectinrezeptor antagonisten enthaltend
WO2000035492A2 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
EP1140179A2 (de) * 1998-12-23 2001-10-10 G.D. SEARLE & CO. Verwendung von einem integrinantagonist zusammen mit einem cox-2 hemmer in der behandlung von neoplasie
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
PT1156823E (pt) * 1999-02-12 2009-01-08 Scripps Research Inst Métodos para tratamento de tumores e metástases utilizando uma combinação de terapias anti-angiogénicas e imunitárias
AU4187200A (en) * 1999-04-01 2000-10-23 Biostratum, Inc. The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
WO2000067771A1 (en) * 1999-05-06 2000-11-16 The Burnham Institute Antiangiogenic endostatin peptides, endostatin variants and methods of use
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US6685914B1 (en) * 1999-09-13 2004-02-03 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
EP1223962A4 (de) * 1999-09-23 2004-01-21 Scripps Research Inst Verfahren und zusammensetzungen zum hemmen der adhäsionsbildung
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
WO2001024823A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Cd40 antagonist for treating psoriasis
ES2383763T3 (es) 1999-12-22 2012-06-26 The Scripps Research Institute Composiciones farmacéuticas que comprenden Src y/o Yes y su utilización
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
JP4039856B2 (ja) * 2000-02-03 2008-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 インテグリン発現阻害剤
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
US20010053766A1 (en) * 2000-02-11 2001-12-20 Janardan Kumar Method of treating disorders of the eye
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6835806B2 (en) 2000-04-03 2004-12-28 Phoenix Pharmaceuticals, Inc. Cell growth regulation system
WO2001077145A2 (en) 2000-04-12 2001-10-18 Amersham Health As Integrin binding peptide derivatives
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US20030104573A1 (en) * 2000-09-11 2003-06-05 Shimkets Richard A. Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
CA2423656A1 (en) * 2000-10-02 2002-04-11 Anthony Montgomery Methods and compositions for enhancing angiogenesis
US6632835B2 (en) 2001-02-22 2003-10-14 Nanodesign Inc. Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
DE10109136A1 (de) * 2001-02-26 2002-09-12 Cytotools Gmbh Mittel, die die Apoptose bei an der Wundheilung beteiligten Zellen inhibieren
WO2002070007A1 (en) * 2001-03-02 2002-09-12 Medimmune, Inc. Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
WO2002085405A2 (en) 2001-04-24 2002-10-31 Merck Patent Gmbh COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
SE0101854L (sv) * 2001-05-28 2002-11-29 Bioneris Ab Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
EP1414491A4 (de) * 2001-07-09 2005-07-06 Elan Pharm Inc Verfahren zur hemmung der toxizität von amyloid
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
NZ530156A (en) 2001-07-10 2007-04-27 Ge Healthcare As Peptide-based compounds for targeting integrin receptors for use as diagnostic imaging agents
EP1573025A4 (de) * 2001-07-27 2006-07-19 Univ Kansas Medical Center Kristallstruktur des typ-iv-collagen-nc1-domäne-hexamers
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US20030119834A1 (en) * 2001-09-05 2003-06-26 Bamdad Cynthia C. Compositions and methods of treatment of cancer
ES2486269T3 (es) 2001-10-22 2014-08-18 The Scripps Research Institute Compuestos que eligen anticuerpos como diana
EP1474162A1 (de) * 2002-02-14 2004-11-10 MERCK PATENT GmbH Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
EP1474168A1 (de) * 2002-02-15 2004-11-10 Richard Brunner 7s immunglobulin zur behandlung der gefässneubildung in der aderhaut des auges
AU2003217930A1 (en) * 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
WO2003075741A2 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
EP1499352A4 (de) * 2002-04-12 2006-10-11 Medimmune Inc Rekombinante anti-interleukin-9-antikörper
AU2003247869C1 (en) 2002-07-15 2009-12-24 Board Of Regents, The University Of Texas System Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
CA2493341A1 (en) * 2002-07-23 2004-01-29 The Regents Of The University Of Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
GB0217018D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 1
WO2004058044A2 (en) * 2002-11-19 2004-07-15 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
WO2004066956A2 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
US7335359B2 (en) * 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
CN1747970A (zh) 2003-02-06 2006-03-15 三肽公司 抗原/抗体或配体/受体糖基化的特异性交换剂
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
CA2520518A1 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of angiogenic disorders
WO2005016966A2 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
CA2527621A1 (en) * 2003-05-30 2004-12-23 Centocor, Inc. Method of inhibiting tumor growth with anti-tissue factor antibodies
US20050170455A1 (en) * 2003-06-20 2005-08-04 Qun-Yong Zhou Novel prokineticin receptor isoforms and methods of use
JP2007512347A (ja) * 2003-11-26 2007-05-17 デューク・ユニバーシティー 緑内障を予防するかまたは治療する方法
ES2809302T3 (es) 2004-01-22 2021-03-03 Univ Miami Formulaciones de coenzima Q10 para tratar tumores sólidos mediante administración intravenosa
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
CA2554537A1 (en) * 2004-02-17 2005-09-01 Cancervax Corporation Method and composition for angiogenesis inhibition
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US7723483B2 (en) * 2004-05-07 2010-05-25 The University Of North Carolina At Chapel Hill Method for enhancing or inhibiting insulin-like growth factor-I
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
EP1745073A2 (de) * 2004-05-14 2007-01-24 Receptor Biologix, Inc. Isoformen eines zelloberflächenrezeptors und verfahren zu deren identifizierung und anwendung
ES2450541T3 (es) 2004-06-04 2014-03-25 The Scripps Research Institute Composiciones para el tratamiento de enfermedades neovasculares
EP1771565B1 (de) * 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivate
US20060029544A1 (en) * 2004-08-06 2006-02-09 The Regents Of The University Of California Office Of Technology Transfer Receptor-binding cyclic peptides and methods of use
AU2005277641A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
KR100679100B1 (ko) * 2004-10-29 2007-02-06 엘지.필립스 엘시디 주식회사 수평 전계 인가형 액정 표시 패널 및 그 제조방법
CN101124243A (zh) * 2004-12-23 2008-02-13 莫尔梅德股份有限公司 缀合产物
WO2006111925A2 (en) * 2005-04-18 2006-10-26 Sloan-Kettering Institute For Cancer Research Inhibition of tumorigenesis by inhibition of a6b4 integrin
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
US20060286148A1 (en) * 2005-05-18 2006-12-21 Ppd, Inc. Method of forming implants
WO2006138429A2 (en) 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CA2619654A1 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
CA2637387A1 (en) 2006-01-18 2007-07-26 Simon Goodman Specific therapy using integrin ligands for treating cancer
EP2243488B1 (de) 2006-01-19 2013-08-14 Eyegene Inc. Peptidhaltige pharmazeutische Zusammensetzung zur Behandlung von mit dem Gefässsystem in Zusammenhang stehenden Krankheiten
SG172692A1 (en) * 2006-06-12 2011-07-28 Symphogen As Pan-cell surface receptor- specific therapeutics
EP2851064A3 (de) 2006-07-11 2015-08-05 Roy C. Levitt Prävention und Therapie von Rhinosinusitis mit proinflammatorischen Zytokinhemmern
PT2068889T (pt) 2006-08-10 2020-01-30 Roy C Levitt Anakinra para uso no tratamento da síndrome da bronquiolite obliterante
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
EP2441464B1 (de) 2007-01-18 2014-04-09 Merck Patent GmbH Integrin-liganden zur verwendung in der behandlung von darmkrebs
DK2025685T3 (da) * 2007-08-15 2013-09-02 Canadian Blood Services Monoklonale antistoffer mod BETA3-integriner.
AU2008312580A1 (en) * 2007-10-16 2009-04-23 Symphogen A/S Compositions comprising optimized Her1 and Her3 multimers and methods of use thereof
US8034905B2 (en) 2007-11-09 2011-10-11 Affitech Research, AS Anti-VEGF antibody compositions and methods
EP2990487A1 (de) 2008-05-08 2016-03-02 Asuragen, INC. Zusammensetzungen und verfahren in zusammenhang mit der mirna-modulation von neovaskularisation oder angiogenese
WO2010011347A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
US9090874B2 (en) 2008-10-31 2015-07-28 University Of Louisville Research Foundation, Inc. Olfactory epithelial-derived stem cells and methods of use therefor
EP2374002A1 (de) 2008-12-23 2011-10-12 GE Healthcare UK Limited Anwendung einer auf 99mtc-peptid basierenden verbindung als knochenmark-bildgebungsmittel
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
EP2445534A2 (de) 2009-05-25 2012-05-02 Merck Patent GmbH Kontinuierliche verabreichung von cilengitid in der krebstherapie
FR2949782B1 (fr) * 2009-09-04 2015-10-16 Isp Investments Inc Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
CN103153328A (zh) 2010-07-16 2013-06-12 默克专利股份有限公司 肽在乳腺癌和/或骨转移灶的治疗中的用途
CA2827052C (en) 2011-02-11 2022-08-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
RU2531502C2 (ru) * 2011-08-09 2014-10-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ повышения ангиогенной активности стромальных клеток жировой ткани
RU2481115C1 (ru) * 2011-10-13 2013-05-10 Общество с ограниченной ответственностью Научно-Производственное Объединение "Тюменькриобанк" Средство для заживления ран "целльгель", способ его получения и способ лечения ран различной этиологии полученным средством
US9775803B2 (en) 2011-10-19 2017-10-03 Samsung Electronics Co., Ltd. Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US9969791B2 (en) * 2012-06-07 2018-05-15 National Cheng Kung University Modified fibronectin fragments or variants and uses thereof
RU2015106333A (ru) 2012-08-31 2016-10-27 Зэ Юниверсити Оф Норз Каролина Эт Чапел Хилл Моноклональные антитела для стимуляции или ингибирования инсулиноподобного фактора роста 1 (igf-1)
US9587001B2 (en) 2012-10-19 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
US20150315154A1 (en) 2012-12-07 2015-11-05 Council Of Scientific & Industrial Research Histidinylated cationic amphiphiles, process for preparation therof and their liposomal formulation
CN105358708A (zh) * 2013-03-14 2016-02-24 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
WO2018145109A1 (en) 2017-02-06 2018-08-09 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
CN110662559A (zh) 2017-03-31 2020-01-07 加利福尼亚大学董事会 用于靶向并杀死ALPHA-V BETA-3(αvβ3)-阳性癌症干细胞（CSC）和治疗耐药癌症的组合物和方法
KR102171433B1 (ko) * 2018-05-25 2020-11-02 고려대학교 산학협력단 조직 재생을 위한 Substance P 펩타이드가 고정된 피브린 젤 및 이의 제조방법
CN113557246B (zh) * 2019-07-24 2023-09-01 韩国基础科学支援研究院 靶向αvβ3整联蛋白的单域抗体
AU2020324391A1 (en) * 2019-08-02 2022-01-20 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (CSCS) and treating drug resistant and metastatic cancers
EP4204094A1 (de) 2020-08-27 2023-07-05 Enosi Therapeutics Corporation Verfahren und zusammensetzungen zur behandlung von autoimmunerkrankungen und krebs

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
EP0341303A4 (de) * 1987-11-19 1990-06-27 Scripps Clinic Res Monoklonaler antikörper gegen den rgd-gerichteten adhäsionsrezeptor von endothelialen zellen.
JPH01169343A (ja) 1987-12-25 1989-07-04 Nippon Sheet Glass Co Ltd ガラス板の切口欠点検出装置
IE64346B1 (en) * 1988-01-19 1995-07-26 Moses Judah Folkman Growth inhibiting agent and the use thereof
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5575815A (en) 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5686566A (en) 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5262520A (en) * 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
EP0470569B1 (de) * 1990-08-08 1995-11-22 Takeda Chemical Industries, Ltd. Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff
CA2048078A1 (en) * 1990-11-15 1992-05-16 Wolfgang A. Wrasidlo Chemical modification of antibodies for creation of immunoconjugates
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
EP0633945B1 (de) * 1992-04-03 1998-12-30 Genentech, Inc. Antikörper gegen alpha v beta 3 integrin
SK57693A3 (en) * 1992-06-18 1994-07-06 Merck Patent Gmbh Linear peptides and pharmaceutical agents on their base
UA43823C2 (uk) 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
US5677181A (en) 1992-10-29 1997-10-14 The Australian National University Angiogenesis inhibitory antibodies
US6955900B1 (en) * 1993-02-02 2005-10-18 The Scripps Research Institute Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof
DE4310643A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
AU1172495A (en) † 1993-11-05 1995-05-23 Centocor Inc. Platelet-specific chimeric immunoglobulin and methods of use therefor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19538741A1 (de) 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate

Also Published As

Publication number Publication date
HK1013960A1 (en) 1999-09-17
ES2211901T3 (es) 2004-07-16
NZ548433A (en) 2008-04-30
SI0754059T2 (sl) 2011-12-30
JP2006273862A (ja) 2006-10-12
DK0754059T4 (da) 2011-09-19
FI963692A0 (fi) 1996-09-18
KR100327081B1 (ko) 2002-10-18
US20080175840A1 (en) 2008-07-24
US7595051B2 (en) 2009-09-29
NZ283022A (en) 2001-05-25
NO322441B1 (no) 2006-10-09
CA2184493C (en) 2010-05-11
US20040265317A1 (en) 2004-12-30
HU9602541D0 (en) 1996-11-28
US5753230A (en) 1998-05-19
US20040258691A1 (en) 2004-12-23
NZ511293A (en) 2005-06-24
US5766591A (en) 1998-06-16
ATE534403T1 (de) 2011-12-15
SI0754059T1 (en) 2004-06-30
US20050002936A1 (en) 2005-01-06
CA2184493A1 (en) 1995-09-28
HUT76086A (en) 1997-06-30
CZ294650B6 (cs) 2005-02-16
CN1161152C (zh) 2004-08-11
AU1995295A (en) 1995-10-09
RU2162712C2 (ru) 2001-02-10
US7354586B2 (en) 2008-04-08
CN1151120A (zh) 1997-06-04
US7482007B2 (en) 2009-01-27
JP4758281B2 (ja) 2011-08-24
JP4268222B2 (ja) 2009-05-27
EP1468695A1 (de) 2004-10-20
EP1410807B1 (de) 2010-12-08
EP0754059A4 (de) 1997-07-30
ATE255907T1 (de) 2003-12-15
MX9604145A (es) 1998-05-31
SK119096A3 (en) 1997-07-09
EP0754059B1 (de) 2003-12-10
FI963692A (fi) 1996-09-18
PT1468695E (pt) 2012-02-09
US6887473B1 (en) 2005-05-03
DK0754059T3 (da) 2004-04-13
HU221988B1 (hu) 2003-03-28
ES2211901T5 (es) 2011-12-12
EP1410807A1 (de) 2004-04-21
EP0754059B2 (de) 2011-08-24
NO963894L (no) 1996-11-18
ATE490784T1 (de) 2010-12-15
DK1410807T3 (da) 2011-03-07
ES2355074T3 (es) 2011-03-22
EP1468695B1 (de) 2011-11-23
FI121916B (fi) 2011-06-15
NO963894D0 (no) 1996-09-17
DE69536128D1 (de) 2011-01-20
PT754059E (pt) 2004-04-30
ZA952214B (en) 1996-02-08
DE69532279T3 (de) 2011-11-17
CZ271196A3 (cs) 1998-01-14
ES2376850T3 (es) 2012-03-20
DE69532279T2 (de) 2004-09-16
DK1468695T3 (da) 2012-02-27
JPH10500398A (ja) 1998-01-13
EP0754059A1 (de) 1997-01-22
KR970701564A (ko) 1997-04-12
AU709645B2 (en) 1999-09-02
UA44729C2 (uk) 2002-03-15
US7329406B2 (en) 2008-02-12
WO1995025543A1 (en) 1995-09-28
SK284586B6 (sk) 2005-07-01

Similar Documents

Publication Publication Date Title
DE69532279D1 (de) Methoden und zusammensetzung zur inhibition der angiogenese
ATE513908T1 (de) Antiangiogenische polypeptide und verfahren zur angiogenesehemmung
AR243728A1 (es) Metodo para producir una composicion humectante de tejidos epiteliales.
DE3881405D1 (de) Antientzuendungsmittel.
DE69733137D1 (de) Inhibitoren von picornavirus 3c protease und verfahren zur herstellung und verwendung
NO971568D0 (no) Analoger av keratinocyttvekstfaktor
PL295838A1 (en) Method of renovating railroad tracks and set of machinery therefor
ATE131920T1 (de) Verfahren zur isolierung von rohren
DE59709922D1 (de) Pflaster zur transdermalen anwendung von pergolid
PL319078A1 (en) Method of obtaining pallidipine-modified inhibitor of collagen induced aggregation of thrombocytes
EP0450086A4 (en) Kit for immunoassay of human tissue plasminogen activator/human plasminogen activator inhibitor complex and method of immunoassay
ATE200414T1 (de) Verwendung eines mittels zur haarbehandlung
BG102060A (en) The use of alendronate for osteoporosis prevention
DE69621805D1 (de) Bowman-birk-inhibitorzusammensetzungen zur behandlung von entzündungskrankheiten
DE3780757D1 (de) Antigestagene zur hemmung der uterinen prostaglandinsynthese.
ES2146607T3 (es) Mezcla proteolitica que contiene escarasa y metodo de aislar la misma.
UA27856C2 (uk) Атравматична голка та спосіб її виготовлення
ATA6084A (de) Verfarhen zur oberflaechenpruefung von stahlstraengen sowie einrichtung zur durchfuehrung des verfahrens
ATA26293A (de) Verfahren zur herstellung und anwendung eines gesichtsmikrofonsystems
ATA119496A (de) Verfahren zur verringerung der menge des schmutzkondensats und einrichtung zur durchführung des verfahrens
ITBO940511A0 (it) Simulatore sperimentale per prove invecchiamento accelerato materiali ceramici
EP0402857A3 (de) Verwendung von 17-beta-Cyclopropylaminoandrosten-Derivaten

Legal Events

Date Code Title Description
8363 Opposition against the patent
R102 Epo decision maintaining patent in amended form now final

Ref document number: 754059

Country of ref document: EP

R102 Epo decision maintaining patent in amended form now final

Ref document number: 754059

Country of ref document: EP

Effective date: 20110824